News

Managed Healthcare Executive1d
FDA Panel Challenges Hormone Replacement Therapy Risks
A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...
Healio1d
FDA panel calls for label changes, more education on menopausal hormone therapy
Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...
Hosted on MSN1y
Winona Menopause Review - Is It Worth It For Hormone Therapy (HRT)? - MSN
Winona is a telehealth company that offers hormone replacement therapy (HRT) for menopause. The company provides FDA-approved bioidentical HRT treatments, which have been found to provide relief ...
Becker's Hospital Review7y
FDA OKs hormone therapy for vaginal condition tied to menopause: 4 ...
The FDA approved TherapeuticsMD’s hormone therapy Imvexxy for a vaginal condition linked to low estrogen levels during menopause, the company announced May 30. 1. Imvexxy is intended to treat ...
Reuters1y
US FDA extends review of Ascendis Pharma's hormone disorder therapy
The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday.
FiercePharma1y
Another delay for Ascendis' hormone therapy as FDA extends review by 3 ...
It’s been a long wait for Ascendis Pharma to score FDA approval for its hormone replacement therapy TransCon PTH (palopegteriparatide). And, now, it’ll take another three months for the U.S ...
Nasdaq1y
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Shares of Ascendis Pharma ASND lost more than 5% on Tuesday after management announced that the FDA extended the review period for its regulatory filing for a hormone replacement therapy by an ...
AOL1y
US FDA extends review of Ascendis Pharma's hormone disorder therapy - AOL
(Reuters) -The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday ...